sub-q gentamicin

PreclinicalSmall molecule

sub-q gentamicin is one of 6 small molecule programs targeting Surgical Site Infections. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Surgical Site InfectionsUnknown status

Surgical Site InfectionsPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Surgical Site Infections

#DrugCompanyPhaseTrials

Betadine

BBecton, Dickinson and Company

Phase 3

1 2

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

2 3

Ancef

BBaxter Healthcare Corporation

Preclinical

2 4

Bactroban

PPadagis LLC

Preclinical

1 5

Amoxicillin/clavulanic Acid

Lundbeck

Preclinical

1 6

sub-q gentamicin

DDallas VA Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Surgical Site Infections1 trial

Effectiveness for Interventions to Minimize Surgical Site Infections

Unknown status·—·N/A·NCT01153191·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sub-q gentamicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sub-q gentamicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sub-q gentamicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dallas VA Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDallas VA Medical Center

sub-q gentamicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Surgical Site Infections1 trial

References

Drug Info

Quick Facts

Related News